查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
脊髓性肌萎縮症治療市場規模、份額和趨勢分析報告：按類型（1or2型）,治療方法（基因療法,藥物）,藥物（Spinraza,Zolgenma）,給藥途徑,地區細分預測2022-2030年
市場調查報告書
商品編碼
1170873

脊髓性肌萎縮症治療市場規模、份額和趨勢分析報告：按類型（1or2型）,治療方法（基因療法,藥物）,藥物（Spinraza,Zolgenma）,給藥途徑,地區細分預測2022-2030年

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type1, Type 2), By Treatment (Gene Therapy, Drug), By Drug (Spinraza, Zolgensma), By Route Of Administration, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 95 Pages | 商品交期: 2-10個工作天內

價格

脊髓性肌萎縮症治療市場的增長和趨勢

根據 Grand View Research, Inc. 的一項新研究，到 2030 年，全球脊髓性肌萎縮症治療市場預計將達到 180 億美元。 預計從 2022 年到 2030 年，複合年增長率將達到 18.6%。 這種增長可歸因於產品批准和發布的增加。 例如，2020 年 8 月，由 Genentech 開發的 Evrysdi（risdiplam）獲得美國食品藥品監督管理局批准，用於治療 2 個月及以上兒童患者的脊髓性肌萎縮症（SMA）。

2020 年 5 月，諾華公司還獲得歐盟委員會 (EC) 有條件批准 SMA 候選藥物 Zolgensma (onasemnogene abeparvovec) 用於治療 SMA 患者。 它是歐洲唯一批准的基因治療藥物。 2021 年 3 月，PTC Therapeutics 獲得了 EMA 的 Evrysdi（risdiplam）上市許可，用於治療 1 型、2 型和 3 型脊髓性肌萎縮症患者。 因此，預計產品批准數量的增加將推動脊髓性肌萎縮症藥物市場的發展。

Novartis AG 通過其全球管理訪問計劃 (MAP) 為 SMA 患者提供免費藥物支持。 該計劃向北美、南美、亞洲、澳大利亞、歐洲和非洲等大陸符合條件的 SMA 患者免費提供 100 劑 Zolgensma。 這樣，對 Zolgensma 的這種支持計劃的存在也加強了促銷活動並有助於增加收入。

在全球範圍內輕鬆獲得 SMA 新生兒篩查和診斷工具應該成為常規方法的一部分。 這將確保早期診斷和及時的 DeepL 治療。 例如，2021 年 7 月，在北卡羅來納州教堂山的 UNC 醫療中心，嬰兒夏洛特通過早期檢查新生兒篩查計劃被診斷患有脊髓性肌萎縮症，這是脊髓性肌萎縮症 (SMA) 的裡程碑，並接受了基因治療。 此類篩查計劃有望促進疾病的早期診斷和治療。

此外，製藥公司還與研究機構進行了多次大規模合作，以開發治療脊髓性肌萎縮症患者的新療法。 例如，2021 年 3 月，PTC Therapeutics, Inc. 和 The Spinal Muscular Atrophy Foundation 開展了一項研究合作，以推進科學研究並開發治療 SMA 患者的新療法。

然而，與治療相關的高成本和用於臨床試驗目的的參與者人數較少可能會限制預測期內的市場增長。 與孤兒藥研發相關的高成本是產品價格上漲的主要因素。 例如，最常用的 SPINRAZA 每次注射成本約為 125,000 美元，每年約 750,000 美元。 此外，Zolgensma (AVXS-101) 每次治療的費用為 210 萬美元。

脊髓性肌萎縮症藥物市場報告要點

由於 1 型脊髓性肌萎縮症患者的高患病率和治療產品的廣泛可用性，按產品類型劃分，1 型細分市場在 2021 年佔據了最大的市場份額

p>

在治療方面，由於市場滲透率不斷提高，基因治療領域預計在預測期內增長最快。Zolgenma 是唯一在 37 個國家批准用於治療 SMA 患者的基因療法。

由於支持性報銷政策的存在和產品知名度的提高，2021 年 SPINRAZA 細分市場在藥物方面佔據主導地位。 SPINRAZA 現在可以在三個歐洲國家完全兌換：意大利、挪威和荷蘭。

在給藥途徑方面，注射劑將在 2021 年主導市場，因為 SMA 患者靜脈給藥具有高安全性、有效性和耐受性

亞太地區預計在預測期內增長最快。 該地區的增長歸因於新產品進入該地區。 例如，2021 年 7 月，F. Hoffmann-La Roche Ltd 在印度推出了用於治療脊髓性肌萎縮症患者的 Evrysdi（risdiplam）。

內容

第1章調查方法及範圍

  • 市場細分
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的內容
    • 主要信息列表
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 全球市場：CAGR 計算
  • 調查假設
  • 二級信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場概覽

第 3 章市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
  • 監管框架
  • 描繪滲透率和增長前景
  • 管道分析
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • PESTEL 分析

第 4 章全球脊髓性肌萎縮症治療市場：細分分析，按類型，2018-2030

  • 全球脊髓性肌萎縮症治療市場：類型變化分析
  • 類型 1
  • 類型 2
  • 類型 3
  • 類型 4

第 5 章全球脊髓性肌萎縮症治療市場：細分分析，按治療方式，2018-2030

  • 全球脊髓性肌萎縮症治療市場：治療波動分析
  • 基因治療
  • 醫學

第 6 章全球脊髓性肌萎縮症治療市場：按藥物細分分析，2018-2030

  • 全球脊髓性肌萎縮症治療市場：藥物變異分析
  • 斯皮拉扎
  • 佐爾根斯瑪 (AVXS-101)
  • 每天
  • 其他

第 7 章全球脊髓性肌萎縮症治療市場：細分分析，按給藥途徑，2018-2030

  • 全球脊髓性肌萎縮症治療市場：給藥途徑差異分析
  • 口語
  • 注入

第 8 章脊髓性肌萎縮症治療市場：2018-2030 年各地區細分分析

  • 脊髓性肌萎縮症治療市場：區域差異分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 意大利
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中東和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

第 9 章全球脊髓性肌萎縮症治療市場：競爭分析

  • 主要市場進入者的近期趨勢和影響分析
    • 對主要交易和戰略聯盟的分析
      • 新產品發布
      • 併購
      • 合作夥伴關係和合同
  • 公司分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 熱圖分析
  • 公司市場分析
  • 供應商情況
    • 主要分銷商和渠道合作夥伴列表
    • 潛在最終用戶列表
    • 2021 年主要參與者的市場份額分析
  • 2021 年公司市場份額
    • 競爭儀表板分析
  • 私人公司
    • 主要初創公司名單
    • 本地網絡地圖
  • 公司簡介
    • 百健
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 諾華公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Ionis Pharmaceuticals Inc.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Biohaven 製藥公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 細胞動力學
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • Scholar Rock, Inc.
      • 公司簡介
      • 財務業績
      • 產品基準
    • PTC 療法
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • NMD 製藥公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-2-68038-626-4

Spinal Muscular Atrophy Treatment Market Growth & Trends:

The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030, according to a new study by Grand View Research, Inc. This is expected to expand at a CAGR of 18.6% from 2022 to 2030. This growth can be attributed to the increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged two months and older with spinal muscular atrophy (SMA).

In addition, in May 2020, Novartis AG received conditional approval to its SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) to treat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.

Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of Zolgensma at free of charge to eligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and also aid in generating revenue.

Global SMA newborn screening and easy access to diagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access to treatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected to boost early diagnosis and treatment of disease.

Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered into research collaboration to advance scientific research and developing new treatment to treat patients with SMA.

However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related to research and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.

Spinal Muscular Atrophy Treatment Market Report Highlights:

  • By type, the type-1 segment held the largest market share in 2021 due to higher prevalence and wide availability of products for the treatment of patients with type-1 spinal muscular atrophy
  • By treatment, the gene therapy segment is expected to be the fastest growing segment over the forecast period due to increase market penetration. Zolgensma is the only approved gene therapy in 37 countries to treat patient with SMA
  • By drug, the Spinraza segment dominated the market in 2021 due to presence of supportive reimbursement policies and increasing awareness about products. Currently, Spinraza is applicable for full reimbursement in three European countries Italy, Norway, Netherlands
  • By route of administration, the injection segment dominated the market in 2021 due to high safety, efficacy, and tolerability associated with infusion drugs to SMA patients through this route of administration
  • Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of region is attributable to the entry of new products into the region. For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR'S internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
    • 1.3.6 List of primary sources
  • 1.4 Information or data analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Regulatory framework
  • 3.3 Penetration and Growth Prospect Mapping
  • 3.4 Pipeline Analysis
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
    • 3.5.2 Market restraint analysis
  • 3.6 PESTEL Analysis

Chapter 4 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Global Spinal Muscular Atrophy Treatment Market: Type Movement Analysis
  • 4.2 Type 1
    • 4.2.1 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.3 Type 2
    • 4.3.1 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4 Type 3
    • 4.4.1 Type 3 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5 Type 4
    • 4.5.1 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Treatment, 2018 - 2030 (USD Million)

  • 5.1 Global Spinal Muscular Atrophy Treatment Market: Treatment Movement Analysis
  • 5.2 Gene Therapy
    • 5.2.1 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Drug
    • 5.3.1 Drug market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Drug, 2018 - 2030 (USD Million)

  • 6.1 Global Spinal Muscular Atrophy Treatment Market: Drug Movement Analysis
  • 6.2 Spinraza
    • 6.2.1 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Zolgensma (AVXS-101)
    • 6.3.1 Zolgensma (AVXS-101) market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Evrysdi
    • 6.4.1 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Others
    • 6.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 7.1 Global Spinal Muscular Atrophy Treatment Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 Injection
    • 7.3.1 Injection market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Spinal Muscular Atrophy Treatment Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Spinal Muscular Atrophy Treatment Market: Regional Movement Analysis
    • 8.1.1 North America
      • 8.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.2 U.S.
      • 8.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.3 Canada
      • 8.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.2 Europe
      • 8.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.2 U.K.
      • 8.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.3 Germany
      • 8.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.4 France
      • 8.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.5 Spain
      • 8.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.6 Italy
      • 8.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.3 Asia Pacific
      • 8.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.2 Japan
      • 8.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.3 China
      • 8.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.4 India
      • 8.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 Australia
      • 8.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 South Korea
      • 8.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.4 Latin America
      • 8.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.2 Brazil
      • 8.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.3 Mexico
      • 8.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.4 Argentina
      • 8.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.5 Middle East & Africa
      • 8.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.2 South Africa
      • 8.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.3 Saudi Arabia
      • 8.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.5 United Arab Emirates
      • 8.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Global Spinal Muscular Atrophy Treatment Market: Competitive Analysis

  • 9.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 9.1.1 Major deals & strategic alliances analysis
      • 9.1.1.1 New Product Launches
      • 9.1.1.2 Mergers and Acquisitions
      • 9.1.1.3 Partnerships & Agreements
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
    • 9.2.3 Emerging Players
    • 9.2.4 Heat Map Analysis
  • 9.3 Company Market Position Analysis
  • 9.4 Vendor Landscape
    • 9.4.1 List of Key Distributors and Channel Partners
    • 9.4.2 List of Potential End Users
    • 9.4.3 Key Company Market Share Analysis, 2021
  • 9.5 Company Market Share, 2021
    • 9.5.1 Competitive Dashboard Analysis
  • 9.6 Private Companies
    • 9.6.1 List of Key Emerging Companies
    • 9.6.2 Regional Network Map
  • 9.7 Company Profiles
    • 9.7.1 Biogen
      • 9.7.1.1 Company overview
      • 9.7.1.2 Financial performance
      • 9.7.1.3 Product benchmarking
      • 9.7.1.4 Strategic initiatives
    • 9.7.2 Novartis AG
      • 9.7.2.1 Company overview
      • 9.7.2.2 Financial performance
      • 9.7.2.3 Product benchmarking
      • 9.7.2.4 Strategic initiatives
    • 9.7.3 Ionis Pharmaceuticals Inc.
      • 9.7.3.1 Company overview
      • 9.7.3.2 Financial performance
      • 9.7.3.3 Product benchmarking
      • 9.7.3.4 Strategic initiatives
    • 9.7.4 Biohaven Pharmaceuticals
      • 9.7.4.1 Company overview
      • 9.7.4.2 Financial performance
      • 9.7.4.3 Product benchmarking
      • 9.7.4.4 Strategic initiatives
    • 9.7.5 F. Hoffmann-La Roche Ltd
      • 9.7.5.1 Company overview
      • 9.7.5.2 Financial performance
      • 9.7.5.3 Product benchmarking
      • 9.7.5.4 Strategic initiatives
    • 9.7.6 Cytokinetics
      • 9.7.6.1 Company overview
      • 9.7.6.2 Product benchmarking
      • 9.7.6.3 Strategic initiatives
    • 9.7.7 Scholar Rock, Inc.
      • 9.7.7.1 Company overview
      • 9.7.7.2 Financial performance
      • 9.7.7.3 Product benchmarking
    • 9.7.8 PTC Therapeutics
      • 9.7.8.1 Company overview
      • 9.7.8.2 Financial performance
      • 9.7.8.3 Product benchmarking
      • 9.7.8.4 Strategic initiatives
    • 9.7.9 NMD Pharma A/S
      • 9.7.9.1 Company overview
      • 9.7.9.2 Financial performance
      • 9.7.9.3 Product benchmarking
      • 9.7.9.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 4 Global Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 Global Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 Global Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 11 U.S. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 U.S. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 15 Canada Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Canada Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 19 Europe Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Europe Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 23 Germany Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Germany Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Germany Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 27 U.K. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 U.K. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 U.K. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 U.K. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 31 France Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33 France Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 France Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 35 Italy Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 37 Italy Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Italy Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 39 Spain Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 40 Spain Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 41 Spain Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Spain Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 47 Japan Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Japan Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Japan Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Japan Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 51 China Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 China Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 China Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 China Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 55 India Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 India Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 57 India Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 India Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 59 South Korea Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 61 South Korea Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 63 Australia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 64 Australia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 65 Australia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 Australia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 67 Latin America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 69 Latin America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Latin America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 71 Brazil Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 73 Brazil Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Brazil Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 75 Mexico Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 77 Mexico Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Mexico Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 79 Argentina Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 81 Argentina Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 91 South Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 South Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 93 South Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 South Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 95 UAE Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 UAE Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 97 UAE Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 UAE Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Spinal Muscular Atrophy Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Spinal Muscular Atrophy Treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Spinal muscular atrophy treatment market driver impact
  • Fig. 14 Spinal muscular atrophy treatment market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's
  • Fig. 17 Strategy mapping
  • Fig. 18 Spinal muscular atrophy treatment market: Type outlook and key takeaways
  • Fig. 19 Spinal muscular atrophy treatment market: Type movement analysis & market share 2021 & 2030
  • Fig. 20 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Type 3 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Spinal muscular atrophy treatment market: Treatment outlook and key takeaways
  • Fig. 25 Spinal muscular atrophy treatment market: Treatment movement analysis & market share 2021 & 2030
  • Fig. 26 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Drug market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Spinal muscular atrophy treatment market: Drug outlook and key takeaways
  • Fig. 29 Spinal muscular atrophy treatment market: Drug movement analysis & market share 2021 & 2030
  • Fig. 30 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Zolgensama market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Spinal muscular atrophy treatment market : Regional outlook and key takeaways
  • Fig. 35 Regional outlook, 2021 & 2030
  • Fig. 36 North America
  • Fig. 37 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S.
  • Fig. 39 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Canada
  • Fig. 41 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.K.
  • Fig. 45 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Italy
  • Fig. 51 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific
  • Fig. 55 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Japan
  • Fig. 57 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • Fig. 58 China
  • Fig. 59 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 India
  • Fig. 61 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea
  • Fig. 63 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Australia
  • Fig. 65 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America
  • Fig. 67 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil
  • Fig. 69 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Mexico
  • Fig. 71 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina
  • Fig. 73 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Middle East & Africa
  • Fig. 75 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa
  • Fig. 77 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia
  • Fig. 79 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 UAE
  • Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Market differentiators
  • Fig. 83 Key company market share analysis, 2021
  • Fig. 84 Company market position analysis
  • Fig. 85 Competitive dashboard analysis
  • Fig. 86 Regional network map